Portal de Periódicos da CAPES

Clinical Pharmacokinetics of Moxonidine

1992; Lippincott Williams & Wilkins; Volume: 20; Issue: Supplement 4 Linguagem: Inglês

10.1097/00005344-199220004-00008

1533-4023

H Weimann, Marion Rudolph,

Pharmacology and Obesity Treatment

Summary: The pharmacokinetic profile of moxonidine was determined in healthy volunteer and patient populations. Moxonidine is rapidly and almost completely absorbed from the gastrointestinal tract. The drug is not subject to first-pass metabolism; its absolute bioavailability is 88%. Only 7.2% is bound to plasma proteins. Moxonidine is predominantly eliminated as unchanged drug via the renal route with a plasma half-life of approximately 2 h. Concurrent food intake does not influence the systemic availability of moxonidine, nor does drug accumulation occur after repeated administration. The systemic availability is increased in renal impairment, necessitating does adjustment in patients with reduced renal function. Aging does not affect the pharmacokinetics to a clinically relevant extent. Moxonidine can be coadministered with drugs such as digoxin, hydro-chlorothiazide, and glibenclamide without risk of pharmacokinetic interactions.